A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Ifinatamab deruxtecan (Primary) ; Amrubicin; Lurbinectedin; Topotecan
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IDeate-2; IDeate-Lung02
- Sponsors Daiichi Sankyo Inc
Most Recent Events
- 13 Nov 2024 Planned number of patients changed from 468 to 540.
- 07 Sep 2024 According to Daiichi Sankyo media release, company is looking forward to see additional results from this trial.
- 01 Aug 2024 According to Daiichi Sankyo media release, company today announced first patient has been dosed in IDeate-Lung02 Phase 3 trial. The initiation of this IDeate-Lung02 trial is based on updated results from a subgroup analysis of the IDeate-PanTumor01.